(BUSINESS WIRE)– Exact Sciences Corp. (Nasdaq:EXAS) today announced that during 2014 it completed and reported a diagnostic result for 4,024 Cologuard tests, more than 4,000 physicians wrote at least one prescription for the test and that as of December 31, the patient compliance rate was 74.6 percent. The Company estimates revenue during the fourth quarter of 2014 from Cologuard was approximately $1.5 million. Exact Sciences has not completed preparation of its financial statements for 2014 and this revenue estimate is based on preliminary data… Read more
Shares of Exact Sciences Corp closed last Friday at $29.16. EXAS has a 1-year high of $29.97 and a 1-year low of $10.69. The stock’s 50-day moving average is $26.89 and it’s 200-day moving average is $21.50.
On the ratings front, Exact Sciences Corp has been the subject of a number of recent research reports. In a report published on January 5, analyst Bruce Jackson from Lake Street Capital initiated coverage with a Buy rating on EXAS and a price target of $33, which implies an upside of 13.2% from current levels. Separately, on December 18, Goldman Sachs` Isaac Ro assigned a Buy rating to Exact Sciences Corp shares and has a price target of $32.
In total, one research analyst has rated the stock with a Sell rating, One research analyst has assigned a Hold rating and 9 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $29.16 which is -12.6% under where the stock closed last Friday.
Exact Sciences Corp is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer.